Abstract
In November 2013, a delayed release (DR) tablet formulation of posaconazole was approved with improved absorption compared to suspension. There have not been studies demonstrating the appropriate dose for antifungal prophylaxis in lung transplant recipients (LTR). The current labeled dose for prophylaxis is 300mg daily. Our goal is to determine the most appropriate dose of posaconazole for prophylaxis in LTR and correlate serum concentrations with different dosing regimens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
